FTE UTILIZATION
85.0%
6.8 / 8 FTE
ACTIVE TRIALS
4
of 5 max
ENROLLMENT RATE
3.9
patients/month
PERFORMANCE SCORE
68
out of 100
MONTHLY OP COST
$62K
20% overhead
ACTIVE TRIALS AT THIS SITE
| PROTOCOL | STATUS | ENROLLMENT | SCREEN FAILURES | FTE |
|---|---|---|---|---|
APEX-301 Advanced Non-Small Cell Lung Cancer | 82 / 120 68% | 12 | 3.0 | |
CARDIO-SHIELD-2 Heart Failure with Reduced Ejection Fraction | 64 / 100 64% | 13 | 2.5 | |
METABOFIX-1 Type 2 Diabetes Mellitus | 64 / 90 71% | 9 | 2.0 |
RECRUITMENT POOLS BY THERAPEUTIC AREA
Cardiology
1,720 of 2,100 available
18.1%
+30/mo
Endocrinology
1,320 of 1,600 available
17.5%
+22/mo
PERFORMANCE BY THERAPEUTIC AREA
| THERAPEUTIC AREA | TRIALS | AVG ENROLLMENT | SCREEN FAILURE | DROPOUT |
|---|---|---|---|---|
| Cardiology | 7 | 4.3/mo | 25.0% | 10.0% |
| Endocrinology | 5 | 3.4/mo | 27.0% | 12.0% |
SITE INFORMATION
PRINCIPAL INVESTIGATOR
Dr. James Mitchell, MD
ADDRESS
1250 Union Avenue
Memphis, TN 38104
Memphis, TN 38104
CONTACT
james.mitchell@medpoint.com
(901) 555-0145
CERTIFICATIONS
ACRPCITIGCP
SPECIALTIES
CardiologyEndocrinology
CAPACITY BY THERAPEUTIC AREA
Cardiology
2 / 3
Endocrinology
2 / 3
HISTORICAL PERFORMANCE
Trials Completed12
On-Time Rate75%
Budget Accuracy±8.1%
Avg Screen Failure26.0%
Avg Dropout11.0%